A subunit vaccine encoding glycoprotein holds potential to protect snakehead (Channa argus) from snakehead vesiculovirus infection

Snakehead vesiculovirus (SHVV) is one of the most harmful viral diseases to the snakehead farming industry. Subunit vaccines with highly protective effects strongly depend on the type of vaccine antigen. In order to screen the potential antigen proteins with efficient immunogenicity and reactogenicity, the glycoprotein (G), matrix protein (M), nucleoprotein (N) and phosphoprotein (P) of SHVV were molecular cloned, sequences analyzed and prokaryotic expressed in this study, then four recombinant proteins were served as subunit vaccines to immunize snakehead by intraperitoneal injection to evaluate the immune effects based on the indexes including the serum antibody level, nonspecific enzyme activity, immune-related gene expression and relative percent survivals (RPS). The results showed that compared with control group, the serum antibody levels and T-AOC activities were significantly higher in all four subunit vaccine groups, the serum ACP and AKP activities in four subunit vaccine groups were higher with different degree, and the detected immune-related genes expression levels were remarkably higher in four subunit vaccine groups except IL-8 gene in spleen of rP group. Among four subunit vaccines, rG protein displayed better immune effect than other three proteins. Besides, the RPS of rG group was highest with 83.3%, followed by rM (66.7%), rN (50.0%) and rP (8.3%), respectively. The above results indicated that glycoprotein was a better candidate protective antigen of SHVV and held potential to protect Snakehead from SHVV infection in the type of subunit vaccine.